- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 11:46 | Amgen to invest $600m in new US science and innovation hub | ||
| Di | Chinese drugmakers prep for looming semaglutide generics horizon | ||
| Di | Trump blames Covid-19 drugmakers for fuelling CDC turmoil | ||
| Di | NVIDIA-backed Charm secures $80m to advance AML drug | ||
| Di | Oxford University and Ellison Institute link for AI vaccine research | ||
| Di | China's NMPA conditionally approves Boehringer's tablets for NSCLC | ||
| Mo | ESC 2025: Higher leg muscle scores reduce cardiovascular risk independent of BMI | ||
| Mo | CDMO insights podcast series: Our Experience is Your Strength | Episode #5 Sustainable packaging | ||
| Mo | Advancing diagnostics reagent development for emerging and rare diseases | ||
| Mo | ESC 2025: Novo Nordisk's Wegovy superior to Zepbound in reducing CV events | ||
| Mo | Eisai's Leqembi unlocks at-home dosing with FDA autoinjector approval | ||
| Mo | Santhera and Ikris sign distribution agreement for DMD drug in India | ||
| Mo | FDA approves Sanofi's BTK inhibitor for immune thrombocytopenia | ||
| Mo | VPAG stalemate threatens to exclude innovative medicines from the UK | ||
| Fr | Teva brings first generic GLP-1 to US market with Saxenda copycat approval | ||
| Fr | Chickenpox jab to be included on England's childhood vaccination programme | ||
| Fr | Outlook's wet AMD candidate hit with second FDA snub in two years | ||
| Fr | Health Canada issues NOC to AbbVie's upadacitinib for giant cell arteritis | ||
| Fr | MHRA approves GSK's oral antibiotic for UTIs in females | ||
| Do | Podcast: Migration of clinical studies | ||
| Do | Four drugs race for first bispecific ADC approval | ||
| Do | Novo Nordisk enlists srRNA developer Replicate in $550m deal | ||
| Do | Cell and gene therapies on correction course but not sinking | ||
| Do | FDA approves mRNA vaccines for new Covid-19 season amid political tension | ||
| Do | AI psychosis sees users 'co-creating delusions with technology' - expert |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .